# **Table of Contents**

State/Territory Name: Washington

State Plan Amendment (SPA)#: WA-24-0020

This file contains the following document in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Pages

# DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



#### **Center for Medicaid and CHIP Services**

# **Medical Benefits Health Programs Group**

July 15, 2024

Susan Birch, Director Dr. Charissa Fotinos, Medicaid Director Health Care Authority PO Box 45502 Olympia, WA 98504-5010

Dear Susan Birch and Dr. Fotinos,

The CMS Division of Pharmacy team has reviewed Washington State Plan Amendment (SPA) 24-0020 received in the CMS Medicaid Services OneMAC application on May 20, 2024. This SPA proposes to add coverage of prescribed drugs that are not covered outpatient drugs in cases of a drug shortage, as well as describe the reimbursement for prescribed drugs that are not covered outpatient drugs.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 24-0020 is approved with an effective date of April 1, 2024. Our review was limited to the materials necessary to evaluate the SPA under applicable federal laws and regulations.

We are attaching a copy of the signed CMS-179 form, as well as the pages approved for incorporation into Washington's state plan. If you have any questions regarding this amendment, please contact Lisa Shochet at (410) 786-5445 or <a href="mailto:lisa.shochet@cms.hhs.gov">lisa.shochet@cms.hhs.gov</a>.

Sincerely,



Cynthia R. Denemark, R.Ph. Director Division of Pharmacy

cc: Ann Myers, Section Manager & State Plan Coordinator, WA Health Care Authority Donna L. Sullivan, PharmD, MS, Chief Pharmacy Officer, WA Health Care Authority Edwin Walaszek, Washington State Lead, Division of Program Operations, CMS

	1 to 1918 to 1900 per 1900 to	
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER 2. STATE 2. 4 — 0 0 2 0 WA	
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL	
	SECURITY ACT  XIX  XXI	
TO: CENTER DIRECTOR  CENTERS FOR MEDICAID & CHIP SERVICES  DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE  April 1, 2024	
5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a FFY 2024 \$ 0	
Section 1902a of the Social Security Act	b. FFY 2025 \$ 0	
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	PAGE NUMBER OF THE SUPERSEDED PLAN SECTION     OR ATTACHMENT (If Applicable)	
Attachment 3.1-A page 30	Attachment 3.1-A page 30 (TN# 08-012) Attachment 3.1-B page 30 (TN# 08-012)	
Attachment 3.1-B page 30 Supplement A to Attachment 4.19-B page 1	Supplement A to Attachment 4.19-B page 1 (TN# 23-0050)	
9. SUBJECT OF AMENDMENT	1	
Pharmacy Update This State Plan Amendment proposes to add covering in cases of a drug shortage, where the state determines cover FDA) is medically necessary.		
10. GOVERNOR'S REVIEW (Check One)		
GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED: EXEMPT	
St	ate Plan Coordinator	
12. TYPED NAME	POB 42716 Olympia, WA 98504-2716	
Charissa Fourios, IVID, IVISC	Olympia, WA 98304-2716	
13. TITLE Medicaid and Behavioral Health Medical Director		
14. DATE SUBMITTED May 20, 2024		
FOR CMS US	E ONLY	
	DATE APPROVED	
May 20, 2024  PLAN APPROVED - ONE	July 15, 2024	
	). SIGN	
20. TYPED NAME OF APPROVING OFFICIAL 21	. TITLE OF APPROVING OFFICIAL	
Cynthia R. Denemark, R.Ph.	Director, Division of Pharmacy	
22. REMARKS		
Pen and Ink change authorized by the state on 7/11/2024 to update the	ne language in Box 9.	

#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State	WASHINGTON	
-------	------------	--

AMOUNT, DURATION, AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY

#### a. Prescribed drugs

### **Drug Coverage**

- (1) Covered outpatient drugs as defined in Section 1927 (k)(2) of the Act are those which are prescribed for a medically accepted indication and produced by any manufacturer, which has entered into and complies with an agreement under Section 1927(a) of the Act.
- (2) Prescriptions written as a result of an EPSDT visit will be approved as ordered by the prescriber.
- (3) Drugs excluded from coverage as provided by Section 1927(d) (2) of the Act are designated in Attachment 3.1-A and 3.1-B, pages 32a and 32b of this plan. Experimental drugs are excluded from coverage.
- (4) Drug shortages. Prescribed drugs that are not covered outpatient drugs (including drugs authorized for import by the Food and Drug Administration) are covered when medically necessary during drug shortages identified by Food and Drug Administration (FDA).

## **Prior Authorization**

- (5) Prescription drugs may be subject to prior authorization by the agency to ensure that drugs are prescribed and dispensed appropriately.
- (6) The agency determines which prescription drugs may require prior authorization by reviewing the drug(s) for the following:
  - Safety
  - Potential for abuse or misuse
  - Narrow therapeutic index
  - High cost when less expensive alternatives are available
  - (7) Prior authorization programs for covered outpatient drugs provide for a response within 24 hours of a request for prior authorization and provides for the dispersing of at least a 72-hours supply of medications in emergency situations.

#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

MACHINICTON

State	WASHINGTON	

AMOUNT, DURATION, AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY

12. a. Prescribed drugs

# **Drug Coverage**

Ctoto

- (1) Covered outpatient drugs as defined in Section 1927 (k)(2) of the Act are those which are prescribed for a medically accepted indication and produced by any manufacturer, which has entered into and complies with an agreement under Section 1927 (a) of the Act.
- (2) Prescriptions written as a result of an EPSDT visit will be approved as ordered by the prescriber.
- (3) Drugs excluded from coverage as provided by Section 1927(d)(2) of the Act are designated in Attachment 3.1-A and 3.1-B, pages 32a and 32b of this plan. Experimental drugs are excluded from coverage.
- (4) Drug shortages. Prescribed drugs that are not covered outpatient drugs (including drugs authorized for import by the Food and Drug Administration) are covered when medically necessary during drug shortages identified by at least one of the following:
  - The United States Food and Drug Administration (US FDA)
  - The American Society of Health-System Pharmacists (ASHP)

#### **Prior Authorization**

- (5) Prescription drugs may be subject to prior authorization by the agency to ensure that drugs are prescribed and dispensed appropriately.
- (6) The agency determines which prescription drugs may require prior authorization by reviewing the drug(s) for the following:
  - Safety
  - Potential for abuse or misuse
  - Narrow therapeutic index
  - High cost when less expensive alternatives are available
- (7) Prior authorization programs for covered outpatient drugs provide for a response within 24 hours of a request for prior authorization and provides for the dispensing of at least a 72-hours supply of medications in emergency situations.

#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State:	WASHINGTON	

### REIMBURSEMENT FOR PHARMACY SERVICES

- I. General Information
  - 1. Prescription drug reimbursement through Point-of-Sale (POS) is based on:
    - a. The standard 11-digit National Drug Code (NDC) (5-4-2 format); and
    - b. The quantity filled.
  - 2. Total reimbursement for a covered outpatient drug does not exceed the lesser of actual acquisition cost (AAC), plus a professional dispensing fee or the provider's usual and customary charge. The AAC is calculated as the lowest of:
    - a. National Average Drug Acquisition Cost (NADAC);
    - b. Maximum allowable cost (MAC);
    - c. Federal Upper Limit (FUL); or
    - d. The provider's usual and customary (U&C) charge to the non-Medicaid population.
    - e. The provider's submitted ingredient cost.

Where NADAC does not exist, Wholesale Acquisition Cost (WAC) is used as the basis for the reimbursement.

- 3. The Agency reimburses prescribed drugs that are not covered outpatient drugs and specialty drugs in accordance with the methodology listed in Section 2 above.
- 4. The Agency reimburses nominally priced drugs at the provider's actual acquisition cost (AAC), plus a professional dispensing fee.
- 5. The Agency reimburses for 340B discounted drugs at the provider's 340B actual acquisition cost and only when the billing provider is a federally qualified PHS-entity billing with an NPI or NABP number listed on the Office of Pharmacy Affairs national Medicaid exclusion file.
- 6. The Agency does not cover 340B discounted drugs dispensed by contract pharmacies.
- 7. The Agency does not cover investigational drugs. Investigational drugs are not a covered service under Washington's Medicaid pharmacy program.
- 8. The Agency reimburses drugs purchased through the Federal Supply Schedule (FSS) at the provider's actual acquisition cost, plus a professional dispensing fee.
- 9. The Agency reimburses drugs purchased through the Indian Health Services (IHS) in accordance with Section 2 above , plus a professional dispensing fee.